Literature DB >> 8869381

Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

A Salmaggi1, A Dufour, M Eoli, E Corsini, L La Mantia, G Massa, A Nespolo, C Milanese.   

Abstract

Serum interleukin 10 (IL10) levels were assessed in patients with multiple sclerosis who were either in a stable or active clinical condition. The levels were compared with values in healthy controls. Lower IL10 levels than in controls were seen in multiple sclerosis patients, regardless of clinical disease activity. Low IL10 levels were also seen in patients with systemic lupus erythematosus. No clear-cut relationships emerged between IL10 levels and those of tumour necrosis factor alpha and transforming growth factor beta, or between IL10 and lymphocyte subsets in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869381     DOI: 10.1007/bf00878525

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

Authors:  K Adachi; T Kumamoto; S Araki
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

3.  TGF-beta-like activity produced during regression of exacerbations in multiple sclerosis.

Authors:  J Beck; P Rondot; P Jullien; J Wietzerbin; D A Lawrence
Journal:  Acta Neurol Scand       Date:  1991-11       Impact factor: 3.209

4.  High levels of "complexed" interleukin-6 in human blood.

Authors:  L T May; H Viguet; J S Kenney; N Ida; A C Allison; P B Sehgal
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI.

Authors:  J Oger; L F Kastrukoff; D K Li; D W Paty
Journal:  Neurology       Date:  1988-11       Impact factor: 9.910

6.  Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.

Authors:  J Link; S Fredrikson; M Söderström; T Olsson; B Höjeberg; A Ljungdahl; H Link
Journal:  Ann Neurol       Date:  1994-02       Impact factor: 10.422

7.  Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  N Tsukada; M Matsuda; K Miyagi; N Yanagisawa
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

8.  Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.

Authors:  G Del Prete; M De Carli; F Almerigogna; M G Giudizi; R Biagiotti; S Romagnani
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

9.  Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases.

Authors:  S Jander; F Heidenreich; G Stoll
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

10.  Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations.

Authors:  J Oger; L Kastrukoff; M O'Gorman; D W Paty
Journal:  J Neuroimmunol       Date:  1986-07       Impact factor: 3.478

View more
  9 in total

1.  IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.

Authors:  M Gelati; E Lamperti; A Dufour; E Corsini; E Venegoni; C Milanese; A Nespolo; A Salmaggi
Journal:  Ital J Neurol Sci       Date:  1997-08

2.  Epstein-Barr virus in oral shedding of children with multiple sclerosis.

Authors:  Carmen Yea; Raymond Tellier; Patrick Chong; Garrett Westmacott; Ruth Ann Marrie; Amit Bar-Or; Brenda Banwell
Journal:  Neurology       Date:  2013-09-06       Impact factor: 9.910

3.  Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

Authors:  V Ozenci; M Kouwenhoven; Y M Huang; P Kivisäkk; H Link
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

4.  IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines.

Authors:  Xinyuan Li; Jietang Mai; Anthony Virtue; Ying Yin; Ren Gong; Xiaojin Sha; Stefanie Gutchigian; Andrew Frisch; Imani Hodge; Xiaohua Jiang; Hong Wang; Xiao-Feng Yang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

5.  TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica.

Authors:  Giselle Pentón-Rol; Majel Cervantes-Llanos; Gregorio Martínez-Sánchez; José A Cabrera-Gómez; Carmen M Valenzuela-Silva; Omar Ramírez-Nuñez; Mayté Casanova-Orta; María A Robinson-Agramonte; Ileana Lopategui-Cabezas; Pedro A López-Saura
Journal:  J Inflamm (Lond)       Date:  2009-06-02       Impact factor: 4.981

6.  Evaluation of TNF-α, IL-10 and IL-6 Cytokine Production and Their Correlation with Genotype Variants amongst Tuberculosis Patients and Their Household Contacts.

Authors:  Lavanya Joshi; Meenakshi Ponnana; Ramya Sivangala; Lakshmi Kiran Chelluri; Prathiba Nallari; Sitaramaraju Penmetsa; Vijayalakshmi Valluri; Sumanlatha Gaddam
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

7.  Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility.

Authors:  Hongyan An; Chai Lim; Gilles J Guillemin; Ute Vollmer-Conna; William Rawlinson; Katherine Bryant; Nicodemus Tedla
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

8.  Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects.

Authors:  Reza Nasrnezhad; Sohrab Halalkhor; Farzin Sadeghi; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2021-08-02       Impact factor: 5.590

Review 9.  Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.